Welcome to the beta version of the MaRS Innovation website.
We have refreshed the site’s design to make better use of its existing functionality while showcasing our projects.
The new design includes these additions and changes:
TORONTO, Ontario, October 4, 2012—Baxter International Inc. and MaRS Innovation, a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in therapeutics and drug discovery technologies.
Information about Baxter and MaRS Innovation’s partnership is also available in French.
The partnership’s shared vision for delivering novel, transformative therapeutic technologies will benefit Canadians and others around the world. Baxter and MaRS Innovation will identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
TORONTO (Ontario), le 4 octobre 2012 – Baxter International Inc. et MaRS Innovation, un centre d’excellence en commercialisation et en recherche, ont établi un partenariat stratégique afin de commercialiser des technologies en phase de développement qui constituent des méthodes novatrices sur le plan des technologies thérapeutiques et de découverte de médicaments.
Information about MaRS Innovation and Baxter’s partnership is also available in English.
In the age of ITunes, videotaping lectures or converting existing textbooks into e-books won’t make you the market leader in online education.
Thanks to a new partnership between ClevrU, and NewMindsets Inc., facilitated by MaRS Innovation and York University’s commercialization office, Canadian technology and content promises to establish the second-generation online learning standard for millions of students worldwide.
TORONTO, ON – A new program that provides nascent software companies with start-up funds, work space, mentoring and business strategy support, was launched today by the University of Toronto and commercialization partner MaRS Innovation, with support from the MaRS Discovery District.
TechVibes has a profile page for UTEST and covered CoursePeer as part of their students start-ups series.
The new program, called University of Toronto Early Stage Technology (UTEST), is part of a growing ecosystem of incubators and commercialization support services at U of T, including the newly-launched Banting and Best Institute. UTEST is unique among campus incubators in that its companies receive start-up funds—$30,000 each in this inaugural year—and because it accepts companies in the very earliest stages of idea generation, before they’re ready for traditional incubators.
ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.
Sean Fine‘s article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.
A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring after surgery.
Its answer to the shortage of Canadian venture capital in life sciences turned out to be a partnership with a drug company in China.
MaRS Innovation’s Vice-President of Business Development and Physical Sciences Joel Liederman, has published an article in the Financial Post about strategies to mitigate risk within the innovation space.
The article, titled “Innovation Success Means Mitigating Risk,” is featured in the newspaper’s Productive Conversations section.
Encycle Therapeutics, a MaRS Innovation spin-off company, was included in BioCentury‘s companies to watch within the macrocycle chemistry space.
The reference came in Chris Cain‘s article, “Maturing macrocycle chemistry drives explosion of biotech newcos, biopharma deals.”
MISSISSAUGA, Ontario, September 18, 2012 – CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML”) and MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in medical diagnostics.
This story was covered in the Globe and Mail, Canadian Business, 680 News, Reuters, Sympatico.ca, the Huffington Post Canada, Technology Trasnfer Tactics, and the Winnipeg Free Press, among others. It was distributed via Yahoo! Finance, Healthcare Global.com, marketwire and Digital Journal.
Hossein Rahnama, CEO of Flybits, a MaRS Innovation spin-off company, appeared on CBC’s Lang and O’Leary Exchange on August 24, 2012.
Watch Rahnama’s interview on CBC’s Media Player. The interview begins at the 13:40 mark and runs to 19:30.
Rahnama, who is also a professor at Ryerson University and and research director at Ryerson’s Digital Media Zone, was recently named to the MIT Technology Review’s prestigious 35 Inventors Under 35 list for 2012 along with fellow MaRS Innovation inventor Joyce Poon.
He describes his context-aware mobile technology, the importance of adapting research to solve real-world problems, the advantages to running a start-up in Toronto, and growing Flybits while keeping the business in Canada.